Literature DB >> 23753410

HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin II-induced lymphocyte activation.

Sumit R Monu1, Paola Pesce, Komal Sodhi, Massimo Boldrin, Nitin Puri, Larisa Fedorova, David Sacerdoti, Stephen J Peterson, Nader G Abraham, Attallah Kappas.   

Abstract

Type-1 cardiorenal syndrome, characterized by acute kidney dysfunction secondary to cardiac failure and renal arteriolar vasoconstriction, is mediated by the renin-angiotensin-aldosterone axis and sympathetic nervous system activation. Previous reports indicate that angiotensin II modulates immune function and causes recruitment and activation of T-lymphocytes. The goal of this study was to evaluate the effects of postischemic heart failure on renal morphology and circulation and the beneficial effects of heme oxygenase-1 (HO-1) induction in T-lymphocyte-suppressed severe combined immune deficiency (SCID) mice. Mice were divided into 4 groups: sham, myocardial infarction (MI), MI treated with an HO-1 inducer, cobalt protoporphyrin, and with or without stannous mesoporphyrin, an inhibitor of HO activity. Heart and kidney function were studied 30 days after surgery. Fractional area change was reduced 30 days after surgery in both the C57 and SCID MI-groups as compared with their respective controls (P<0.01). Renal Pulsatility Index and renal injury were increased in C57 and SCID MI-groups compared with the sham group. HO-1 induction improved renal vasoconstriction as well as ameliorated renal injury in both the SCID and C57 MI-groups (P<0.01). However, improvement was more evident in SCID mice. In addition, our results showed that plasma creatinine, angiotensin II, and renin were significantly increased in the C57 and SCID MI-groups as compared with their respective controls. HO-1 induction decreased these parameters in both MI groups. Stannous mesoporphyrin reversed the beneficial effect of cobalt protoporphyrin in both mouse strains. The study demonstrates that T-lymphocyte suppression facilitated the HO-1-dependent improvement in the attenuation of type-1 cardiorenal syndrome.

Entities:  

Keywords:  T-lymphocytes; angiotensin II; heart failure; heme oxygenase-1; vasoconstriction

Mesh:

Substances:

Year:  2013        PMID: 23753410      PMCID: PMC3771397          DOI: 10.1161/HYPERTENSIONAHA.111.00495

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

1.  The cardiorenal connection.

Authors:  Lennart G Bongartz; Maarten Jan M Cramer; Branko Braam
Journal:  Hypertension       Date:  2004-02-16       Impact factor: 10.190

2.  Mechanism of heme-heme oxygenase system impairment of endothelium contraction in the spontaneously hypertensive rat.

Authors:  Nader G Abraham; Attallah Kappas
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

3.  Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice.

Authors:  S F Yet; R Tian; M D Layne; Z Y Wang; K Maemura; M Solovyeva; B Ith; L G Melo; L Zhang; J S Ingwall; V J Dzau; M E Lee; M A Perrella
Journal:  Circ Res       Date:  2001-07-20       Impact factor: 17.367

4.  T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats.

Authors:  Carmen De Miguel; Satarupa Das; Hayley Lund; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-10       Impact factor: 3.619

5.  Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.

Authors:  Guangwu Wang; Tariq Hamid; Rachel J Keith; Guihua Zhou; Charles R Partridge; Xilin Xiang; Justin R Kingery; Robert K Lewis; Qianhong Li; D Gregg Rokosh; Rachael Ford; Francis G Spinale; Daniel W Riggs; Sanjay Srivastava; Aruni Bhatnagar; Roberto Bolli; Sumanth D Prabhu
Journal:  Circulation       Date:  2010-04-19       Impact factor: 29.690

6.  Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites.

Authors:  M Bolognesi; D Sacerdoti; M Di Pascoli; P Angeli; S Quarta; A Sticca; P Pontisso; C Merkel; A Gatta
Journal:  Gut       Date:  2005-06-10       Impact factor: 23.059

7.  Cardiorenal Syndrome: The Clinical Cardiologists' Perspective.

Authors:  Eric J Chan; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

8.  [Type 1 cardiorenal syndrome and its possible pathophysiological mechanisms].

Authors:  Grazia Maria Virzi'; Massimo de Cal; Dinna N Cruz; Chiara Bolin; Giorgio Vescovo; Claudio Ronco
Journal:  G Ital Nefrol       Date:  2012 Nov-Dec

9.  Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.

Authors:  S F Yet; M A Perrella; M D Layne; C M Hsieh; K Maemura; L Kobzik; P Wiesel; H Christou; S Kourembanas; M E Lee
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

10.  Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities.

Authors:  Daniel Arthur B Kasal; Ernesto L Schiffrin
Journal:  Int J Hypertens       Date:  2012-05-21       Impact factor: 2.420

View more
  8 in total

1.  Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway.

Authors:  Jian Cao; Peter L Tsenovoy; Ellen A Thompson; John R Falck; Robert Touchon; Komal Sodhi; Rita Rezzani; Joseph I Shapiro; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-02-09       Impact factor: 3.072

Review 2.  Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications.

Authors:  John A McClung; Lior Levy; Victor Garcia; David E Stec; Stephen J Peterson; Nader G Abraham
Journal:  Pharmacol Ther       Date:  2021-09-06       Impact factor: 12.310

Review 3.  Heme Oxygenase-1 Upregulation: A Novel Approach in the Treatment of Cardiovascular Disease.

Authors:  Lars Bellner; Nachum B Lebovics; Rochelle Rubinstein; Yosef D Buchen; Emilia Sinatra; Giuseppe Sinatra; Nader G Abraham; John A McClung; Ellen A Thompson
Journal:  Antioxid Redox Signal       Date:  2020-02-10       Impact factor: 8.401

Review 4.  Heme oxygenase-1 and acute kidney injury.

Authors:  Karl A Nath
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-01       Impact factor: 2.894

5.  Impaired Coronary and Renal Vascular Function in Spontaneously Type 2 Diabetic Leptin-Deficient Mice.

Authors:  Helena U Westergren; Julia Grönros; Suvi E Heinonen; Tasso Miliotis; Karin Jennbacken; Alan Sabirsh; Anette Ericsson; Ann-Cathrine Jönsson-Rylander; Sara Svedlund; Li-Ming Gan
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

6.  Cardioprotective Heme Oxygenase-1-PGC1α Signaling in Epicardial Fat Attenuates Cardiovascular Risk in Humans as in Obese Mice.

Authors:  Shailendra P Singh; John A McClung; Ellen Thompson; Yosef Glick; Menachem Greenberg; Giancarlo Acosta-Baez; Basel Edris; Joseph I Shapiro; Nader G Abraham
Journal:  Obesity (Silver Spring)       Date:  2019-08-23       Impact factor: 5.002

Review 7.  OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention.

Authors:  Stephen J Peterson; Abu Choudhary; Amardeep K Kalsi; Shuyang Zhao; Ragin Alex; Nader G Abraham
Journal:  Diagnostics (Basel)       Date:  2020-11-20

8.  Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography.

Authors:  P Pesce; L Cecchetto; S Brocco; M Bolognesi; K Sodhi; N G Abraham; D Sacerdoti
Journal:  J Ultrasound       Date:  2014-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.